Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation …
A Kolnagou, C Economides, E Eracleous… - …, 2008 - Taylor & Francis
For the past 2–6 years, two groups of thalassemia patients, one of 16 patients on
deferoxamine (DFO) monotherapy (35–80 mg/kg, 2–5 days/week) and the other group …
deferoxamine (DFO) monotherapy (35–80 mg/kg, 2–5 days/week) and the other group …
Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation …
A Kolnagou, C Economides, E Eracleous… - Hemoglobin, 2008 - europepmc.org
For the past 2-6 years, two groups of thalassemia patients, one of 16 patients on
deferoxamine (DFO) monotherapy (35-80 mg/kg, 2-5 days/week) and the other group …
deferoxamine (DFO) monotherapy (35-80 mg/kg, 2-5 days/week) and the other group …
Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation …
A Kolnagou, C Economides, E Eracleous… - …, 2008 - pubmed.ncbi.nlm.nih.gov
For the past 2-6 years, two groups of thalassemia patients, one of 16 patients on
deferoxamine (DFO) monotherapy (35-80 mg/kg, 2-5 days/week) and the other group …
deferoxamine (DFO) monotherapy (35-80 mg/kg, 2-5 days/week) and the other group …
Long Term Comparative Studies in Thalassemia Patients Treated with Deferoxamine or a Deferoxamine/Deferiprone Combination. Identification of Effective Chelation …
A Kolnagou, C Economides, E Eracleous… - …, 2008 - search.ebscohost.com
Abstract For the past 2-6 years, two groups of thalassemia patients, one of 16 patients on
deferoxamine (DFO) monotherapy (35-80 mg/kg, 2-5 days/week) and the other group …
deferoxamine (DFO) monotherapy (35-80 mg/kg, 2-5 days/week) and the other group …